Get a proposal

Neurology · Clinical trials

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About chronic inflammatory demyelinating polyneuropathy (cidp) — and why its trials are hard

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy characterized by progressive or relapsing, symmetric proximal and distal weakness with sensory loss evolving over at least eight weeks, distinguishing it from Guillain-Barré syndrome. Pathophysiology involves both cellular and humoral attack on peripheral myelin; nerve conduction studies show demyelination and CSF often shows albuminocytologic dissociation. A nodal/paranodal antibody subset (e.g., anti-neurofascin-155, anti-contactin-1) responds poorly to standard therapy. First-line disease-modifying options are well established: intravenous immunoglobulin (ICE trial), corticosteroids, and plasma exchange, with subcutaneous immunoglobulin (Hizentra, PATH trial) approved for maintenance to reduce relapse. In 2024 the FcRn antagonist efgartigimod alfa/hyaluronidase (Vyvgart Hytrulo) was approved based on the ADHERE trial, providing a targeted IgG-lowering maintenance option that significantly reduced relapse risk. Treatment aims to induce and maintain improvement while minimizing long-term corticosteroid exposure. Some patients become treatment-dependent, and accurate diagnosis is essential given frequent misdiagnosis.

Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ICD-10-CM
G61.81 — Chronic inflammatory demyelinating polyneuritis

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
Intravenous immunoglobulin (IVIG) (Gamunex-C)2008 (CIDP indication)First-line induction and maintenanceICE (Phase 3)Proportion improved/maintained on adjusted INCAT disability score~54% improved on IVIG vs ~21% placebo; established durable maintenance benefit
Corticosteroids (e.g., prednisone) ((generic))long-establishedFirst-line induction immunotherapyHistorical RCTs; pulsed dexamethasone/methylprednisolone studiesDisability and impairment improvementEffective first-line; limited by long-term steroid toxicity
Subcutaneous immunoglobulin (SCIg) (Hizentra)2018Maintenance therapy to prevent relapsePATH (Phase 3)CIDP relapse or withdrawalRelapse ~33% (0.4 g/kg) and ~39% (0.2 g/kg) vs 63% placebo; enabled home-based maintenance
Efgartigimod alfa/hyaluronidase (Vyvgart Hytrulo)2024Maintenance therapy in adults with CIDPADHERE (Phase 2/3)Time to first clinical deterioration (relapse) in randomized withdrawal~61% reduction in relapse risk vs placebo (hazard ratio ~0.39); FcRn antagonist lowering pathogenic IgG

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in chronic inflammatory demyelinating polyneuropathy (cidp) development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
Fingolimod — FORCIDP (Phase 3)Terminated for futilityThe S1P-receptor modulator did not reduce CIDP relapse/worsening versus placebo, and the trial was stopped early.
Methotrexate — RMC trial (Phase 2/3)No significant steroid/IVIG-sparing benefitFailed to demonstrate meaningful reduction in IVIG or corticosteroid requirement compared with placebo.

Choosing the right endpoint

Primary endpoints that matter in chronic inflammatory demyelinating polyneuropathy (cidp) trials

  • INCAT disability score (adjusted) — Ordinal arm/leg disability scale; the classic CIDP trial primary endpoint (used in ICE).
  • Time to relapse / clinical deterioration — Primary endpoint in randomized-withdrawal maintenance designs such as ADHERE and PATH.
  • I-RODS (Inflammatory Rasch-built Overall Disability Scale) — Patient-reported activity/participation measure increasingly used as a sensitive functional endpoint.
  • Grip strength — Objective, responsive measure of neuromuscular function used as a secondary endpoint.
  • MRC sum score — Composite muscle strength assessment tracking impairment change.

How iNGENū runs chronic inflammatory demyelinating polyneuropathy (cidp) trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

Planning a chronic inflammatory demyelinating polyneuropathy (cidp) trial?
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Request a proposal

Frequently asked questions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials — FAQs

How is CIDP distinguished from Guillain-Barré syndrome?
CIDP progresses or relapses over at least eight weeks, whereas GBS is monophasic and acute (peaking within four weeks). Importantly, CIDP responds to corticosteroids while GBS does not.
What are the standard first-line treatments?
IVIG, corticosteroids, and plasma exchange are all first-line. Subcutaneous immunoglobulin (Hizentra) is approved for maintenance, and efgartigimod (Vyvgart Hytrulo) was approved in 2024 as a targeted maintenance option.
How does efgartigimod work in CIDP?
It is an FcRn antagonist that accelerates degradation of circulating IgG, including pathogenic autoantibodies. In the ADHERE trial it substantially reduced the risk of relapse during randomized withdrawal.

Ready to discuss your chronic inflammatory demyelinating polyneuropathy (cidp) trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal